PREVALENCE AND ASSOCIATED FACTORS OF ASPIRIN NON RESPONSIVENESS IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN DUHOK-IRAQ

Abstract

Background: The anti-platelets action of aspirin is not universal in all patients undergoing percutaneous coronary intervention (PCI). We evaluated the prevalence and associated risk factors of aspirin nonresponsiveness in patients undergoing stenting in Duhok-Iraq. Methods: Eighty patients with coronary artery disease (CAD) undergoing PCI with drug eluting stents from 2015 to 2017 in Duhok-Iraq were enrolled after completion of the first year of dual antiplatelet (Aspirin plus Clopidogrel) while receiving aspirin 100 milligrams regularly. A detailed cardiac assessment, cardiovascular risk factors, and coronary angiographic profile of cases were reviewed. Aspirin responsiveness was assessed by measuring serum thromboxane B2 assay. Then a correlation with associated factors was performed. For major adverse cardiac events, responders and non-responders were followed up for a further two years.Results: The mean age of cases was (59.28± 8.43 years). Thirty-nine were females. The aspirin nonresponsiveness was 14%. None of the risk factors were associated significantly with non responsiveness (p>0.05). Besides, significant differences in rates of adverse cardiac events were absent between responders and non-responders throughout the follow-up period.Conclusions: Aspirin nonresponsiveness is not uncommon among our patients. No clear association with risk factors was detected. Short term adverse cardiac events rate between responder and non-responders was not affected.